September 13, 2021
Investors in Ophthotech Corp. asked a New York federal judge Friday to approve a $29 million cash settlement they had reached with the biopharmaceutical company over claims that it misled shareholders regarding clinical trial phases for a macular degeneration drug.
September 18, 2019
Biopharmaceutical company Ophthotech Corp. must face some, but not all, claims that it misled investors regarding clinical trial phases for a macular degeneration drug, a New York federal judge ruled Wednesday.